ShangPharma Innovation

Abcuro, Inc. is focused on developing immunotherapies aimed at treating autoimmunity and cancer. Incorporated in 2015 and based in Newton, Massachusetts, the company specializes in creating therapeutic antibodies that target novel aspects of the immune system. By employing advanced bioinformatics and analyzing transcription data from human diseases, Abcuro identifies new therapeutic targets and validates them through ex-vivo studies in diseased tissues. This innovative approach aims to enhance treatment strategies and improve patient outcomes in the fields of autoimmunity and oncology.

Valitor, Inc. is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in developing advanced, protein-based drugs and has established pipelines targeting oncology, dermatology, ophthalmology, and orthopedics. Valitor employs novel methods to modify therapeutic proteins, enhancing their pharmacokinetics, target specificity, and bioactivity. This innovative technology platform aims to improve the pharmacological properties of both existing and emerging protein drugs, allowing for more effective treatment strategies for various diseases. By focusing on targeted therapeutic delivery, Valitor seeks to optimize patient outcomes through its next-generation drug development initiatives.

Skyhawk Therapeutics is focused on the discovery and development of small molecule therapeutics aimed at correcting RNA expression. The company utilizes proprietary technology to design small molecules that specifically target binding pocket regions on RNA, ensuring both sequence and structural specificity during critical phases of RNA splicing. This innovative approach enables the development of therapies for various conditions, including cancer, neurological disorders, and rare diseases, particularly those associated with RNA mis-splicing known as exon skipping. Founded in 2015 and headquartered in Waltham, Massachusetts, Skyhawk Therapeutics was previously known as Rare Genetix before rebranding in 2018.